...
首页> 外文期刊>Biopharmaceutics and Drug Disposition >Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability.
【24h】

Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability.

机译:恩丹西酮在大鼠中的剂量依赖性药代动力学:肝和肠首过效应对低生物利用度的贡献。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The pharmacokinetic parameters of ondansetron were evaluated after its intravenous (at doses of 1, 4, 8 and 20 mg/kg) and oral (4, 8 and 20 mg/kg) administration to rats. The gastric, intestinal and hepatic first-pass effects of ondansetron were also evaluated after its intravenous, oral, intraportal, intragastric and intraduodenal administration at a dose of 8 mg/kg to rats. After intravenous and oral administration of ondansetron, the drug exhibits dose-independent pharmacokinetics in rats. After oral administration of ondansetron at a dose of 8 mg/kg, the unabsorbed fraction was 0.0158 of the dose, the extent of absolute oral bioavailability (F) value was 0.0407, and the hepatic and intestinal first-pass effects were 40.0% and 34.2% of the oral dose, respectively. The low F of ondansetron in rats was mainly due to considerable hepatic and intestinal first-pass effects. The lower F of ondansetron in rats (4.07%) than that in humans (62 +/- 15%) was mainly due to greater hepatic metabolism of the drugin rats. Ondansetron was stable in the rat gastric juices and various buffer solutions having pHs ranging from 1 to 13. The equilibrium plasma-to-blood cells partition ratio of ondansetron was 1.74-5.31. Protein binding of ondansetron to fresh rat plasma was 53.2%. Copyright (c) 2008 John Wiley & Sons, Ltd.
机译:在对大鼠进行静脉内(1、4、8和20 mg / kg剂量)和口服(4、8和20 mg / kg)恩丹西酮的药代动力学参数评估。在以8 mg / kg的剂量静脉内,口服,门内,胃内和十二指肠内给药后,还评估了恩丹西酮在胃,肠和肝的首过效应。恩丹西酮静脉和口服给药后,该药物在大鼠中表现出剂量依赖性药代动力学。口服恩丹西酮8 mg / kg剂量后,未吸收分数为剂量的0.0158,绝对口服生物利用度(F)值为0.0407,肝和肠首过效应为40.0%和34.2分别为口服剂量的%。恩丹西酮在大鼠中的低F值主要归因于肝脏和肠道的首过效应。恩丹西酮在大鼠中的F(4.07%)低于人(62 +/- 15%),这主要是由于该药物大鼠的肝脏代谢更高。恩丹西酮在大鼠胃液和各种pH范围为1至13的缓冲液中均稳定。恩丹西酮的平衡血浆与血液细胞分配比为1.74-5.31。昂丹司琼与新鲜大鼠血浆的蛋白结合率为53.2%。版权所有(c)2008 John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号